Atypical Antipsychotic Use is an Independent Predictor for the Increased Mean Platelet Volume in Patients with Schizophrenia: A Preliminary Study

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2014 Feb 12

PMID 24516487

Citations 7

Authors

Murat Semiz

Hasan Yucel

Onder Kavakci

Osman Yildirim

Ali Zorlu

Mehmet Birhan Yilmaz

Zekeriya Kucukdurmaz

Fatih Canan

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular diseases, cardiovascular risk factors, and mortality due to these situations are more frequently encountered in schizophrenic patients when compared with the general population. The mean platelet volume (MPV) is a surrogate biomarker of the platelet activity and an useful prognostic test in cardiometabolic diseases. The aim of this study was to investigate what influenced MPV levels in patients with schizophrenia.

Materials And Methods: We evaluated hospital records of 60 hospitalized schizophrenia patients. Thirty age- and sex-matched healthy control subjects were also included as a control group.

Results: MPV levels were significantly higher in patients who were on atypical antipsychotic drugs than in patients who were not using any drug (9.2 ± 0.8 vs. 8.6 ± 0.8 fL, P = 0.016) and also higher than control group (9.2 ± 0.8 vs. 8.1 ± 0.9 fL, P < 0.001). Furthermore, patients who were not using antipsychotics had higher MPV than control group (8.6 ± 0.8 vs. 8.1 ± 0.9 fL, P = 0.036). Atypical antipsychotic use [Odds ratio (OR) =6.152, 95% confidence interval (CI,) P = 0.003)] and platelet distribution width (OR = 0.989, 95% CI, P = 0.032) were associated with high MPV levels in univariate analysis. In multivariate logistic regression model, only atypical antipsychotics use (OR = 6.152, 95% CI, P = 0.003) was found to be independent predictor of high MPV levels after adjustment of other potential confounders (age, gender, presence of hypertension, diabetes mellitus, hyperlipidemia, and smoking).

Conclusion: MPV seems to be influenced not only by schizophrenia itself but also by atypical antipsychotic drugs. It might be concluded that schizophrenic patients are under increased risk for cardiometabolic diseases and risk factors and this risk is higher in patients on atypical antipsychotic treatment.

Citing Articles

Platelet Parameters in First-Episode Patients with Schizophrenia and Bipolar Disorder.

Almis B, Egilmez O Psychiatry Clin Psychopharmacol. 2024; 31(3):339-343.

PMID: 38765952 PMC: 11082633. DOI: 10.5152/pcp.2021.21695.

New role of platelets in schizophrenia: predicting drug response.

Zhang Y, Zheng Y, Ni P, Liang S, Li X, Yu H Gen Psychiatr. 2024; 37(2):e101347.

PMID: 38616969 PMC: 11015174. DOI: 10.1136/gpsych-2023-101347.

Meta-analysis of peripheral mean platelet volume in patients with mental disorders: Comparisons in depression, anxiety, bipolar disorder, and schizophrenia.

Chen Z, Wang J, Carru C, Sedda S, Nivoli A, Li Z Brain Behav. 2023; 13(11):e3240.

PMID: 37644555 PMC: 10636414. DOI: 10.1002/brb3.3240.

Mean platelet volume, platelet count, and neutrophil/lymphocyte ratio in drug-naïve patients with schizophrenia: a cross-sectional study.

Cabello-Rangel H, Basurto-Morales M, Botello-Aceves E, Pazaran-Galicia O Front Psychiatry. 2023; 14:1150235.

PMID: 37229382 PMC: 10203581. DOI: 10.3389/fpsyt.2023.1150235.

Evaluation of Simple Markers of Inflammation and Systemic Immune Inflammation Index in Schizophrenia, Bipolar Disorder Patients and Healthy Controls.

Inaltekin A, Yagci I Turk Psikiyatri Derg. 2023; 34(1):11-15.

PMID: 36970957 PMC: 10552167. DOI: 10.5080/u26248.

References

Bobes J, Arango C, Garcia-Garcia M, Rejas J . Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res. 2010; 119(1-3):101-9. DOI: 10.1016/j.schres.2010.02.1030. View

De Hert M, Detraux J, van Winkel R, Yu W, Correll C . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. DOI: 10.1038/nrendo.2011.156. View

Ordu S, Ozhan H, Caglar O, Alemdar R, Basar C, Yazici M . Mean platelet volume in patients with dipper and non-dipper hypertension. Blood Press. 2009; 19(1):26-30. DOI: 10.3109/08037050903416402. View

Plein H, Berk M . The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol. 2002; 16(3):229-236. DOI: 10.1002/hup.251. View

Pathansali R, Smith N, Bath P . Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets. 2001; 12(5):292-7. DOI: 10.1080/09537100120058810. View

Yao J, Magan S, Sonel A, Gurklis J, Sanders R, Reddy R . Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2004; 71(3):171-6. DOI: 10.1016/j.plefa.2004.03.011. View

Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W . Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events?. Stroke. 2004; 35(7):1688-91. DOI: 10.1161/01.STR.0000130512.81212.a2. View

Martin J, Shaw T, Heggie J, Penington D . Measurement of the density of human platelets and its relationship to volume. Br J Haematol. 1983; 54(3):337-52. DOI: 10.1111/j.1365-2141.1983.tb02109.x. View

Zornberg G, Jick H . Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet. 2000; 356(9237):1219-23. DOI: 10.1016/S0140-6736(00)02784-7. View

10.

Kario K, Matsuo T, Nakao K . Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992; 14(4):281-7. DOI: 10.1111/j.1365-2257.1992.tb00103.x. View

11.

Yilmaz M, Saricam E, Biyikoglu S, Guray Y, Guray U, Sasmaz H . Mean platelet volume and exercise stress test. J Thromb Thrombolysis. 2004; 17(2):115-20. DOI: 10.1023/B:THRO.0000037666.01018.8c. View

12.

De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S . Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008; 101(1-3):295-303. DOI: 10.1016/j.schres.2008.01.028. View

13.

van Winkel R, Rutten B, Peerbooms O, Peuskens J, van Os J, De Hert M . MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010; 121(1-3):193-8. DOI: 10.1016/j.schres.2010.05.030. View

14.

Martin J, Bath P, Burr M . Influence of platelet size on outcome after myocardial infarction. Lancet. 1991; 338(8780):1409-11. DOI: 10.1016/0140-6736(91)92719-i. View

15.

Hasnain M, Fredrickson S, Vieweg W, Pandurangi A . Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10(3):209-16. DOI: 10.1007/s11892-010-0112-8. View

16.

Meltzer H . Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci. 1995; 3(2):64-75. View

17.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F . A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2008; 166(2):152-63. DOI: 10.1176/appi.ajp.2008.08030368. View

18.

Ryan M, Thakore J . Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002; 71(3):239-57. DOI: 10.1016/s0024-3205(02)01646-6. View

19.

Leucht S, Burkard T, Henderson J, Maj M, Sartorius N . Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007; 116(5):317-33. DOI: 10.1111/j.1600-0447.2007.01095.x. View

20.

Nasrallah H . The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68 Suppl 1:5-11. View